Skip to main content
. 2022 Aug 26;14:910988. doi: 10.3389/fnagi.2022.910988

FIGURE 4.

FIGURE 4

Brain regional chronic microglial activation 1 month after 5 mg/kg i.p LPS administration. (A) Percentage of the marked area by Iba1 in vehicles (white columns) and LPS treated mice (black columns) 30 days post administration. Two-way ANOVA. FBrain Regions (15, 64) = 25.33, p < 0.0001; FTreatment (1, 64) = 44.38, p < 0.0001. FInteraction (15, 64) = 2.069, p < 0.0233, and n = 3 mice per region. Significance: (*) respect relative vehicles. (B) Iba1 positive cell density per mm2 in vehicles (white columns) and LPS treated mice 30 days post administration (black columns). Two way ANOVA. FBrain Regions (15, 64) = 37.93, p < 0.0001; FTreatment (1, 64) = 32.59, p < 0.0001; FInteraction (15, 64) = 1.517, p < 0.1259, and n = 3 mice per region. Significance: (*) respect relative vehicles. (C) Representative images of Iba1 staining in piriform cortex, amygdala and thalamus. Scale bar = 100 um.